BGLC Stock Overview
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioNexus Gene Lab Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$17.88 |
| 52 Week Low | US$0.31 |
| Beta | 1.95 |
| 1 Month Change | 17.03% |
| 3 Month Change | 66.39% |
| 1 Year Change | -85.80% |
| 3 Year Change | -96.45% |
| 5 Year Change | n/a |
| Change since IPO | -82.75% |
Recent News & Updates
Shareholder Returns
| BGLC | US Trade Distributors | US Market | |
|---|---|---|---|
| 7D | 26.8% | -4.0% | -3.7% |
| 1Y | -85.8% | 40.3% | 20.5% |
Return vs Industry: BGLC underperformed the US Trade Distributors industry which returned 40.3% over the past year.
Return vs Market: BGLC underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| BGLC volatility | |
|---|---|
| BGLC Average Weekly Movement | 83.4% |
| Trade Distributors Industry Average Movement | 5.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BGLC's share price has been volatile over the past 3 months.
Volatility Over Time: BGLC's weekly volatility has increased from 63% to 84% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 30 | Lee Tan | www.bionexusgenelab.com |
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments.
BioNexus Gene Lab Corp. Fundamentals Summary
| BGLC fundamental statistics | |
|---|---|
| Market cap | US$14.99m |
| Earnings (TTM) | -US$2.63m |
| Revenue (TTM) | US$9.77m |
1.5x
P/S Ratio-5.7x
P/E RatioIs BGLC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGLC income statement (TTM) | |
|---|---|
| Revenue | US$9.77m |
| Cost of Revenue | US$8.44m |
| Gross Profit | US$1.33m |
| Other Expenses | US$3.96m |
| Earnings | -US$2.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 13.61% |
| Net Profit Margin | -26.91% |
| Debt/Equity Ratio | 0% |
How did BGLC perform over the long term?
See historical performance and comparison